Masimo Co. (NASDAQ:MASI)’s stock price reached a new 52-week high on Thursday . The company traded as high as $152.20 and last traded at $151.75, with a volume of 12860 shares. The stock had previously closed at $149.68.

A number of equities analysts recently weighed in on MASI shares. Stifel Nicolaus increased their price objective on shares of Masimo from $150.00 to $160.00 and gave the stock a “buy” rating in a research report on Friday, May 17th. UBS Group reaffirmed a “buy” rating and set a $25.00 price objective on shares of Infineon Technologies in a research report on Tuesday, May 7th. Piper Jaffray Companies raised their price target on shares of Adverum Biotechnologies from $8.00 to $12.00 and gave the company an “overweight” rating in a research report on Friday, May 17th. Needham & Company LLC reissued a “hold” rating on shares of KLA-Tencor in a research report on Tuesday, May 7th. Finally, BTIG Research cut shares of Masimo from a “buy” rating to a “neutral” rating and set a $134.50 price target for the company. in a research report on Tuesday, April 16th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Masimo has an average rating of “Buy” and an average price target of $154.25.

The firm has a market capitalization of $8.00 billion, a P/E ratio of 50.38, a PEG ratio of 2.99 and a beta of 1.14. The business’s 50-day moving average is $142.62.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Monday, May 6th. The medical equipment provider reported $0.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.04. Masimo had a net margin of 22.49% and a return on equity of 18.61%. The company had revenue of $231.70 million during the quarter, compared to analysts’ expectations of $223.67 million. During the same quarter last year, the company posted $0.75 EPS. The firm’s revenue was up 8.8% compared to the same quarter last year. As a group, analysts anticipate that Masimo Co. will post 3.12 EPS for the current year.

In other news, CEO Joe E. Kiani sold 100,000 shares of Masimo stock in a transaction on Monday, July 1st. The shares were sold at an average price of $150.14, for a total transaction of $15,014,000.00. Following the completion of the sale, the chief executive officer now directly owns 239,241 shares of the company’s stock, valued at approximately $35,919,643.74. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Anand Sampath sold 30,000 shares of Masimo stock in a transaction on Friday, June 14th. The stock was sold at an average price of $142.39, for a total transaction of $4,271,700.00. Following the sale, the executive vice president now directly owns 27,518 shares of the company’s stock, valued at $3,918,288.02. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 186,242 shares of company stock valued at $27,360,053. Corporate insiders own 11.50% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in MASI. Claybrook Capital LLC purchased a new stake in shares of Masimo during the 4th quarter worth $25,000. West Oak Capital LLC purchased a new stake in shares of Masimo during the 1st quarter worth $28,000. FinTrust Capital Advisors LLC purchased a new stake in shares of Masimo during the 1st quarter worth $61,000. Valeo Financial Advisors LLC purchased a new stake in shares of Masimo during the 1st quarter worth $69,000. Finally, Penserra Capital Management LLC purchased a new stake in shares of Masimo during the 1st quarter worth $92,000. 83.03% of the stock is owned by institutional investors and hedge funds.

Masimo Company Profile (NASDAQ:MASI)

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

See Also: What are gap-up stocks?

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.